Research shows exercise is a boon for cancer patients

March 02, 2017

Exercise and/or psychological therapy work better than medications to reduce cancer-related fatigue and should be recommended first to patients, according to a Wilmot Cancer Institute-led study published in JAMA Oncology.

"If a cancer patient is having trouble with fatigue, rather than looking for extra cups of coffee, a nap, or a pharmaceutical solution, consider a 15-minute walk," said lead author Karen Mustian, Ph.D., M.P.H., associate professor in the University of Rochester Medical Center Department of Surgery's Cancer Control Program. "It's a really simple concept but it's very hard for patients and the medical community to wrap their heads around it because these interventions have not been front-and-center in the past," she added. "Our research gives clinicians a valuable asset to alleviate cancer-related fatigue."

Scientists reached their conclusions about exercise and psychological interventions after analyzing the outcomes of 113 unique studies that tested various treatments for cancer-related fatigue. All were randomized clinical trials, the gold standard for evaluating effective treatments. The analysis started with 17,033 abstracts and was whittled down to 113 that met strict criteria of rigorous scientific methods.

More than 11,000 patients were involved in the 113 studies. Nearly half were women with breast cancer; ten studies focused on other types of cancer and enrolled only men.

Data show that exercise alone--whether aerobic or anaerobic--reduced cancer-related fatigue most significantly. Psychological interventions, such as therapy designed to provide education, change personal behavior, and adapt the way a person thinks about his or her circumstances, similarly improved fatigue. Studies that delivered a combination of exercise and psychological therapy had mixed results and researchers cannot say for sure what the best method is for combining treatments to make them effective. Finally, the study showed that drugs tested for treating cancer-related fatigue were not as effective. (Those drugs include stimulants like modafinil, which can be used for narcolepsy, and Ritalin, which treats ADHD.)

"The literature bears out that these drugs don't work very well although they are continually prescribed," Mustian said. "Cancer patients already take a lot of medications and they all come with risks and side effects. So any time you can subtract a pharmaceutical from the picture it usually benefits patients."

All of the participants in the analyzed studies suffered cancer-related fatigue, the most common side effect during and after cancer treatment. This type of fatigue is different from being chronically tired, Mustian said. It's a crushing sensation that's not relieved by rest or sleep, and can persist for months or years. Researchers believe cancer-related fatigue might be the result of a chronic state of inflammation induced by the disease or its treatment. Most concerning, Mustian said, is that fatigue can decrease a patient's chances of survival because it lessens the likelihood of completing medical treatments. She noted that the National Cancer Institute has chosen cancer-related fatigue as a top research priority.

Mustian and several colleagues at Wilmot have been studying exercise in the context of cancer for nearly 15 years. Her studies often test gentle yoga, walking, resistance bands, and other forms of movement as therapies to abate side effects. The Wilmot team also investigates the biological pathways impacted by exercise in cancer patients.
-end-
Co-authors of the current study include several members of Wilmot's Cancer Control group, as well as national experts from the Society of Behavioral Medicine's evidenced-based behavioral medicine committee. The NCI funded the research.

University of Rochester Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.